Year-end Sale % OFF 
Abstract
The outcome of first-episode psychosis (FEP) is highly variable, ranging from early sustained recovery to antipsychotic treatment resistance from the onset of illness. For clinicians, a possibility to predict patient outcomes would be highly valuable for the selection of antipsychotic treatment and in tailoring psychosocial treatments and psychoeducation. This selective review summarizes current knowledge of prognostic markers in FEP. We sought potential outcome predictors from clinical and sociodemographic factors, cognition, brain imaging, genetics, and blood-based biomarkers, and we considered different outcomes, like remission, recovery, physical comorbidities, and suicide risk. Based on the review, it is currently possible to predict the future for FEP patients to some extent. Some clinical features—like the longer duration of untreated psychosis (DUP), poor premorbid adjustment, the insidious mode of onset, the greater severity of negative symptoms, comorbid substance use disorders (SUDs), a history of suicide attempts and suicidal ideation and having non-affective psychosis—are associated with a worse outcome. Of the social and demographic factors, male gender, social disadvantage, neighborhood deprivation, dysfunctional family environment, and ethnicity may be relevant. Treatment non-adherence is a substantial risk factor for relapse, but a small minority of patients with acute onset of FEP and early remission may benefit from antipsychotic discontinuation. Cognitive functioning is associated with functional outcomes. Brain imaging currently has limited utility as an outcome predictor, but this may change with methodological advancements. Polygenic risk scores (PRSs) might be useful as one component of a predictive tool, and pharmacogenetic testing is already available and valuable for patients who have problems in treatment response or with side effects. Most blood-based biomarkers need further validation. None of the currently available predictive markers has adequate sensitivity or specificity used alone. However, personalized treatment of FEP will need predictive tools. We discuss some methodologies, such as machine learning (ML), and tools that could lead to the improved prediction and clinical utility of different prognostic markers in FEP. Combination of different markers in ML models with a user friendly interface, or novel findings from e.g., molecular genetics or neuroimaging, may result in computer-assisted clinical applications in the near future.
Highlights
Naturalistic follow-up studies have found highly divergent outcomes in first-episode psychosis (FEP) [1, 2]
Recovered patients with first episode schizophrenia—defined as patients living independently, working or studying, having absent or stably mild symptoms for 2 years, and having social contacts and participation—showed a significant increase in resilience at 4-year follow-up [20, 38]. These results indicate that individual differences in resilience will differently affect the recovery process [20], stressing the importance of taking resilience into account in outcome studies and using resilience-building strategies
There are already many clinical parameters that predict different outcomes, but these should be transformed into an individual-level prediction, where patients typically have mixed features—some predicting a better outcome, others a worse outcome
Summary
Naturalistic follow-up studies have found highly divergent outcomes in first-episode psychosis (FEP) [1, 2]. Increased leptin in psychosis is mostly explained by a medication effect on weight gain, and a meta-analysis did not find significant changes in drug-naïve patients [132] Peripheral monoamines and their metabolites have been studied as candidate biomarkers for treatment response in FEP. The predictors of a higher suicide risk include the earlier age of onset; a history of previous suicide attempts; the severity of the symptoms of depression, anxiety, and psychosis; substance abuse; being male; a high IQ and better neurocognitive functioning; a high level of education; high socio-economic status; poor premorbid adjustment; living alone; a longer DUP; insight; and a family history of suicide [29, 167, 170, 171]. Treating a comorbid SUD should be an integral part of treatment of FEP
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
